PharmaPoint: Chronic Myeloid Leukemia (CML) - Global Drug Forecast and Market Analysis to 2022 - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

PharmaPoint: Chronic Myeloid Leukemia (CML) - Global Drug Forecast and Market Analysis to 2022

Description:

Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients’ survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems. – PowerPoint PPT presentation

Number of Views:43

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: PharmaPoint: Chronic Myeloid Leukemia (CML) - Global Drug Forecast and Market Analysis to 2022


1
PharmaPoint Chronic Myeloid Leukemia (CML) -
Global Drug Forecast and Market Analysis to
2022
2
Summary
Chronic myeloid leukemia (CML) is a rare
myeloproliferative blood cancer that is
characterized by the presence of the BCR-ABL
fusion protein. The stage of CML is classified as
chronic, accelerated or blast phase, ranging from
least to most severe. Multiple BCR-ABL tyrosine
kinase inhibitors (TKIs) are approved, and are
the standard of care for CML. TKIs have
transformed most cases of the disease into a
manageable, chronic condition. As a result,
patients survival rates and the prevalence of
CML are increasing, placing a growing burden on
global healthcare systems.
W www.bharatbook.com , T  91 22 27810772,
27810773, E  info_at_bharatbook.com
3
Highlights Key Questions Answered - How will the
CML market size and composition change over the
forecast period?  - How will the TKIs be used
differently in lines of therapy and in different
patient segments? - The unmet needs of many CML
patients are relatively low. What remaining needs
exist, and what qualities must potential new
market entrants have to compete in this space? -
Will the entry of generic imatinib influence
physician prescribing patterns? Why or why not? -
What are the strengths and weaknesses of Gleevec,
Tasigna, Sprycel, Bosulif, Iclusig and Synribo,
and how do they stack up against one another?
Which will have the greatest commercial success
over the forecast period? - Do key opinion
leaders believe that discontinuation of TKI
therapy is feasible? For which patients?
W www.bharatbook.com , T  91 22 27810772,
27810773, E  info_at_bharatbook.com
4
Key Findings - Global pressure to cut healthcare
expenditure will influence physicians
prescribing patterns. - Once launched, generic
imatinib will be the most commonly prescribed
first line therapy for chronic phase patients,
the largest and most lucrative segment. This
availability of generics will be the single
greatest factor in the decline of the CML
therapeutics market from 2012-2022. - Of the
recent market entrants Bosulif and Iclusig,
Iclusig will be more commercially successful. It
is a favorite of KOLs because of its potent
efficacy, particularly in patients with the T315I
mutation. However, the uptake of both drugs will
be restricted due to high prices and concerns
about long-term side effects. - There is still
significant unmet need for safe and effective
therapies that can control CML in the accelerated
and blast phases.
W www.bharatbook.com , T  91 22 27810772,
27810773, E  info_at_bharatbook.com
5
Scope - Overview of CML, including epidemiology,
etiology, symptoms, diagnosis, pathology and
treatment guidelines.  - Annualized CML
therapeutics market revenue, annual cost of
therapy and treatment usage pattern data by
patient segment forecast from 2012 to 2022.  -
Key topics covered include strategic competitor
assessment, market characterization, unmet needs,
clinical trial mapping and implications for the
CML therapeutics market  - Pipeline analysis The
CML pipeline is exceptionally weak, due to the
relatively low level of unmet need. Innovative
early-stage projects are highlighted,
supplemented with KOL opinions about the validity
of new targets.  - Analysis of the current and
future market competition in the global CML
market. Insightful review of the key industry
drivers, restraints and challenges. Each trend is
independently researched to provide qualitative
analysis of its implications.
W www.bharatbook.com , T  91 22 27810772,
27810773, E  info_at_bharatbook.com
6
Reasons to buy  Develop business strategies by
understanding the trends shaping and driving the
global CML therapeutics market.  - Drive revenues
by understanding the key trends, innovative
products and technologies, market segments, and
companies likely to impact the global CML
therapeutics market in future.  - Formulate
effective sales and marketing strategies by
understanding the competitive landscape and by
analyzing the performance of various
competitors.  - Identify emerging players with
potentially strong product portfolios and create
effective counter-strategies to gain a
competitive advantage.  - Forecast drug sales in
the global CML therapeutics market from
2012-2022.  - Organize your sales and marketing
efforts by identifying the market categories and
segments that present maximum opportunities for
consolidations, investments and strategic
partnerships.  - Develop and design your
in-licensing and out-licensing strategies through
a review of pipeline products and technologies. 
W www.bharatbook.com , T  91 22 27810772,
27810773, E  info_at_bharatbook.com
7
Table of Contents
  1. Introduction
  2. Disease Overview
  3. Epidemiology
  4. Disease Management
  5. Opportunity and Unmet Need
  6. Pipeline Assessment
  7. Current and Future Players
  8. Market Outlook

W www.bharatbook.com , T  91 22 27810772,
27810773, E  info_at_bharatbook.com
8
To view the full Executive Summary and Table of
Contents, please visit PharmaPoint Chronic
Myeloid Leukemia (CML) - Global Drug Forecast and
Market Analysis to 2022 Contact Us- Call India
91-22-27810772/73 Email id info_at_bharatbook.com
Website www.bharatbook.com Our Blog
https//www.bharatbook.com/blog/
Follow Us On
About PowerShow.com